Veru Inc. (NASDAQ:VERU) Q1 2025 Earnings Call Transcript
Q1 2025 Earnings Call Transcript February 13, 2025 Veru Inc. beats earnings expectations. Reported EPS is $-0.06, ...
Veru Inc.: Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress
Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater ...
Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress
Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary ...
Endocrinology Advisor3d
January 2025 Recap: Drug Pipeline Updates
The table below is a review of notable updates that occurred in January 2025 for investigational products in development.